| 1.13 0.13 (13%) | 08-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.5 | 1-year : | 1.73 |
| Resists | First : | 1.29 | Second : | 1.48 |
| Pivot price | 1.11  |
|||
| Supports | First : | 0.97 | Second : | 0.81 |
| MAs | MA(5) : | 1.03 |
MA(20) : | 1.16 |
| MA(100) : | 1.81 |
MA(250) : | 3.88 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 20.4 |
D(3) : | 11.7 |
| RSI | RSI(14): 44.6 |
|||
| 52-week | High : | 17.95 | Low : | 0.97 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PRFX ] has closed below upper band by 46.7%. Bollinger Bands are 64.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.15 - 1.16 | 1.16 - 1.16 |
| Low: | 0.99 - 0.99 | 0.99 - 1 |
| Close: | 1.12 - 1.13 | 1.13 - 1.14 |
PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations. PRF-110 is presently undergoing assessment in two pivotal Phase 3 clinical trials, specifically for individuals recovering from bunionectomy and hernia repair procedures. The company, which was originally incorporated in 2007 under the name PainReform Ltd., maintains its headquarters in Tel Aviv, Israel.
Mon, 27 Jul 2026
PRF Technologies (Nasdaq: PRFX) details $10M raise, trials and AI energy - Stock Titan
Sat, 25 Jul 2026
PRF Technologies Ltd. Revenue Breakdown – NASDAQ:PRFX - tradingview.com
Tue, 21 Jul 2026
PRF Technologies Plans GridFeed at Event Expected to Draw 2,500+ - Stock Titan
Tue, 21 Jul 2026
PRF Technologies (PRFX) to showcase GridFeed AI trading platform at Energy Trading Week Europe 2026 - Stock Titan
Wed, 15 Jul 2026
Battery storage additions reached 108 GW in 2025; PRF expands AI - Stock Titan
Thu, 18 Jun 2026
PRF Technologies (PRFX) sets up $15M standby share facility with Yorkville - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 844370 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 57 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.35e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -16 % |
| Return on Assets (ttm) | 200 % |
| Return on Equity (ttm) | -38.8 % |
| Qtrly Rev. Growth | 17000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -86.07 |
| EBITDA (p.s.) | -50476.2 |
| Qtrly Earnings Growth | -7.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0.11 |
| Dividend | 0 |
| Forward Dividend | 145660 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|